Austrian biomarker developer BIOCRATES Life Sciences AG (www.biocrates.com)
announced today that it entered a co-marketing agreement with
Canadian-based CHENOMX Inc (www.chenomx.com).
Both enterprises focus on a new and highly promising technology aimed at
generating a metabolic profile of the human organism that can be used to
monitor the effects of disease, nutrition, toxins, environment, or drugs
on an organism.
“The research focus of both BIOCRATES and CHENOMX is to identify and
quantify endogenous metabolites in body fluid or tissue samples and
develop them into powerful biomarkers”
“The research focus of both BIOCRATES and CHENOMX is to identify and
quantify endogenous metabolites in body fluid or tissue samples and
develop them into powerful biomarkers,” says Elgar Schnegg, MBA, Chief
Executive Officer of BIOCRATES. The proprietary, patent-protected
technology platform of BIOCRATES is based on mass spectrometry; CHENOMX
analyzes biological samples utilizing a patented and unique methodology
based on Nuclear Magnetic Resonance (NMR) spectroscopy. Mass
spectrometry offers high sensitivity; NMR offers a broad metabolite
coverage. “The two methods produce complementary data sets with very
little overlap in results. Both tests can be run on the same samples
thus offering a more comprehensive profile,” explains Neil Taylor, Chief
Executive Officer of CHENOMX.